热门资讯> 正文

Lifeward最新外骨骼设备获得FDA批准

2025-03-13 23:22

Lifeward (NASDAQ:LFWD) stock soared on Thursday after it has received 510((k)) FDA clearance for its new personal exoskeleton device, the ReWalk 7.
LFWD is up 42% in morning trade.
The company said that the seventh generation of the ReWalk, a wearable exoskeleton that allows individuals with spinal cord injury to stand and walk again, will begin selling in the United States as soon as the product is available.

More on Lifeward

Lifeward Ltd. (LFWD) Q4 2024 Earnings Call Transcript
Lifeward Non-GAAP EPS of -$0.38 misses by $0.05, revenue of $7.55M misses by $0.29M
Lifeward CEO Larry Jasinski to step down
Seeking Alpha’s Quant Rating on Lifeward
Historical earnings data for Lifeward

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。